Suven Life's scrip gained 3.53 per cent to settle at Rs 227.60 on the BSE. During the day, it rose by 4.16 per cent to Rs 229.
At the NSE, it went up by 3.54 per cent to end at Rs 227.90.
In the process, the company added Rs 91.02 crore to Rs 2,659.02 crore in its market capitalisation.
Pharmaceuticals firm Suven Life Sciences Ltd had yesterday said it has raised Rs 200 crore through QIP route to fund its clinical development programme and capital expenditure.
Post issue the promoters holding will be over 59 per cent as against 64.76 per cent on September 30, 2014.
In a BSE filing, Suven Life Sciences had said, "It has concluded its Rs 200 crore fund raising exercise through the Qualified Institutional Placement (QIP) process."
The funds raised will be effectively deployed to fund the clinical development programme, capital expenditure and for general corporate purposes, it had said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
